A new case report was published on September 18, 2026, in Surgical Neurology International, discussing lanreotide in the context of pituitary tumor surgery. The publication is titled "Endoscopic transsphenoidal surgery for a somatotroph pituitary neuroendocrine tumor associated with an infraoptic course of the anterior cerebral artery: A case report."
The report describes a surgical case involving a somatotroph pituitary neuroendocrine tumor, noted alongside an anatomical variation involving the anterior cerebral artery. It was indexed with PubMed ID 42829594.
This is a case report publication, and no efficacy or outcome data from the study are detailed here. The listing confirms only that the article has been published in the named journal on the stated date. Readers interested in the clinical context of somatotroph pituitary neuroendocrine tumors and associated surgical approaches can consult the full publication for complete methodology and findings.
Lanreotide is an approved compound, and this publication represents new literature associated with its clinical use in neuroendocrine tumor settings. No additional details about results, treatment outcomes, or safety data are provided in this record. For broader background on lanreotide, readers can refer to the compound overview.